Choice of first‐line therapy in metastatic melanoma

Anti–PD‐1, alone or in combination with anti–CTLA‐4, and targeted BRAF therapies comprise the current first‐line systemic therapies for patients with metastatic melanoma. The decision on treatment choice is based on BRAF status, disease status, toxicity, efficacy profiles, comorbidities, and patient...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 125; no. 5; pp. 666 - 669
Main Authors Gibney, Geoffrey T., Atkins, Michael B.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.03.2019
Subjects
Medical treatment
Melanoma
Metastases
Metastasis
Oncology
Patients
Toxic diseases
Toxicity
Online AccessGet full text

Cover

More Information
Summary:Anti–PD‐1, alone or in combination with anti–CTLA‐4, and targeted BRAF therapies comprise the current first‐line systemic therapies for patients with metastatic melanoma. The decision on treatment choice is based on BRAF status, disease status, toxicity, efficacy profiles, comorbidities, and patient preferences.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.31774